Loading...
•
Mar 31, 2021
TransMedics Q1 2021 Earnings Report
TransMedics reported financial results for the first quarter of 2021.
Key Takeaways
TransMedics Group, Inc. reported a net revenue of $7.1 million for the first quarter of 2021, a 6% decrease compared to the first quarter of 2020. U.S. net revenue increased by 11% year-over-year. The gross margin was 68% as compared to 65% in the first quarter of 2020. Net loss for the first quarter of 2021 was $7.9 million compared to $8.9 million in the first quarter of 2020.
Net revenue of $7.1 million in the first quarter of 2021, representing a 6% decrease compared to the first quarter of 2020.
Reported U.S. net revenue growth of 11% year-over-year.
Announced positive FDA advisory committee vote for OCS Heart System.
Announced expectation for mid-July 2021 OCS Liver FDA advisory committee meeting.
Forward Guidance
The company is advancing quickly toward several near term regulatory and commercial catalysts expected in 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...